Gilead Sciences (GILD) Stake Raised by Vident Investment Advisory LLC
Vident Investment Advisory LLC increased its position in shares of Gilead Sciences (NASDAQ:GILD) by 40.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,800 shares of the biopharmaceutical company’s stock after acquiring an additional 19,833 shares during the quarter. Vident Investment Advisory LLC’s holdings in Gilead Sciences were worth $4,929,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in GILD. Financial Advocates Investment Management acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $607,000. Laurel Wealth Advisors Inc. increased its stake in Gilead Sciences by 12.5% in the 4th quarter. Laurel Wealth Advisors Inc. now owns 9,726 shares of the biopharmaceutical company’s stock valued at $696,000 after buying an additional 1,080 shares during the period. Hoylecohen LLC acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $6,202,000. Platinum Investment Management Ltd. increased its stake in Gilead Sciences by 5.0% in the 4th quarter. Platinum Investment Management Ltd. now owns 3,044,930 shares of the biopharmaceutical company’s stock valued at $218,138,000 after buying an additional 145,300 shares during the period. Finally, Verition Fund Management LLC increased its stake in Gilead Sciences by 216.5% in the 4th quarter. Verition Fund Management LLC now owns 24,192 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 16,548 shares during the period. Institutional investors and hedge funds own 78.35% of the company’s stock.
NASDAQ GILD opened at $73.70 on Friday. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The firm has a market cap of $97,058.59, a P/E ratio of 8.61, a PEG ratio of -1.68 and a beta of 1.19. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were issued a $0.57 dividend. The ex-dividend date of this dividend was Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 3.09%. Gilead Sciences’s dividend payout ratio is 26.64%.
In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total value of $2,087,750.00. Following the completion of the sale, the executive vice president now directly owns 62,738 shares of the company’s stock, valued at approximately $5,239,250.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gayle E. Wilson sold 60,000 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the sale, the director now directly owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 308,600 shares of company stock valued at $24,328,226. Insiders own 1.30% of the company’s stock.
Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BMO Capital Markets restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Wells Fargo upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $79.02 to $96.00 in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $88.65.
ILLEGAL ACTIVITY NOTICE: “Gilead Sciences (GILD) Stake Raised by Vident Investment Advisory LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/04/22/gilead-sciences-gild-stake-raised-by-vident-investment-advisory-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.